Surgical Science Sweden Balances Record Quarter With 2026 Risk

Surgical Science Sweden AB ((SE:SUS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Surgical Science Sweden’s latest earnings call struck a cautiously optimistic tone, as management balanced strong operational progress with frank acknowledgment of looming headwinds. Record license revenue, robust FX-adjusted growth and solid cash flow underpinned confidence, but the Intuitive MoU cancellation and margin erosion cast a long shadow over 2026 visibility.

FX-Adjusted Growth Delivers Solid Q4 and Full-Year Sales

Q4 sales reached SEK 269 million, up 15% in local currencies and 7% on a reported basis, illustrating underlying demand despite FX pressure. For the full year, revenue climbed to SEK 992 million, representing 19% growth in local currencies and 12% reported, confirming that the core business is still expanding at a healthy clip.

Record Robotics License Revenues Strengthen Recurring Mix

Licensing in the robotics segment hit an all-time high in Q4, with revenues of SEK 92 million rising 21% year on year. Licenses made up 34% of total revenue versus 30% a year earlier, signaling a continued shift toward higher-quality, recurring income that investors typically reward with higher valuation multiples.

Q4 Profitability Back Above Target Despite Earlier Pressure

Adjusted EBIT in Q4 came in at SEK 46 million, implying an adjusted margin of about 17% and roughly 18% when stripping out restructuring costs. Operating profit of SEK 40 million equated to a 15% margin, in line with the company’s stated goal of maintaining profitability above 15% even in a tougher environment.

Price Increases Support Margins Without Hurting Volumes

Management highlighted an average sales price increase of roughly 9% compared with the year-earlier quarter at fixed exchange rates, notably without significant volume loss. This pricing power offers a key lever to defend margins going forward, and the company expects further positive price effects as existing contracts roll over.

Americas Lead Regional Performance with Strong Rebound

North and South America stood out as the growth engine, with Q4 revenue in the region jumping 43%, driven primarily by the U.S. market. The rebound, combined with stronger pipelines, suggests that earlier softness in the Americas is now firmly behind the company and that this region can support future topline growth.

Robotics Pipeline Broadens as New Products Roll Out

Surgical Science now has relationships with about 20 robotics companies, of which only around five generated license revenue in Q4, highlighting untapped upside. The launch of the RobotiX Express product, featuring 14 exercises, and rising global robotic surgery adoption, including strong procedure growth at major players, underscore the potential of this portfolio.

Development Revenues and Repeat Business Show Customer Stickiness

Development revenues were notably strong in Q4, and the pipeline of ongoing development projects was about 15% larger than at the end of the previous year. Repeat customers accounted for more than 70% of development projects, a sign of strong satisfaction and a foundation for stable, high-margin engineering work.

Robust Cash Generation and Liquidity Underpin Strategy

Operating cash flow improved to SEK 73 million in Q4 from SEK 57 million in the prior-year quarter, tracking the earnings uplift. With a year-end cash balance of SEK 616 million and modest capex needs, the company appears well funded to pursue its strategy, including integration efforts and product investments without stressing the balance sheet.

Intuitive MoU Cancellation Creates a Major 2026 Overhang

The most material negative from the call was Intuitive’s cancellation of the memorandum of understanding around dV5 installations, which had underpinned expectations for future license volumes. Management now expects a SEK 60–90 million hit to 2026 license revenue and has limited visibility on future attach rates, injecting significant uncertainty into medium-term growth.

Full-Year Margin Compression Highlights Cost and FX Pressure

Despite a strong Q4, the adjusted EBIT margin for the full year dropped to 12% from 19% the year before, reflecting a year of margin squeeze. This deterioration underscores that the business is not immune to rising costs, FX headwinds and integration drag, and that sustained margin recovery will be a key metric to watch.

Ultrasound and IU Integration Lag Expectations

Ultrasound revenue, including the acquired Intelligent Ultrasound business, grew 48% versus the prior-year Q4 but still fell short of pro forma expectations. IU posted an operating loss of about SEK 5 million in the quarter, with weaker U.K. NHS demand weighing on sales and demonstrating that synergy capture and integration work are still a work in progress.

Simulator Sales to Device Makers Show Sharp Volatility

Sales of simulators to medical device companies dropped sharply to SEK 21 million in Q4 from SEK 43 million a year earlier, a decline of roughly 51%. Management framed this as a timing issue in larger projects, but the swing highlights how lumpy this revenue stream can be and why investors should brace for quarterly noise.

Asia and China Weakness Weighs on Regional Mix

Asia, particularly China, remained a problem area as regional sales fell 21% in Q4 amid subdued activity and demand. This softness not only hurts growth but also shifts the geographic revenue mix toward other regions, potentially limiting diversification benefits if China’s recovery continues to lag.

FX Headwinds Erode Gross Margin and Earnings

Adverse foreign-exchange moves reduced gross margin to 66% from 68%, with around 2.3 percentage points attributed to currency effects. For the full year, FX shaved about SEK 38 million off “other” items, illustrating that even strong operational performance must work harder just to stand still when currencies move against the company.

Lumpy License and Simulator Revenue Reduces Visibility

Only about five of the roughly 20 robotics customers generated license revenue in Q4, and large batch orders drive meaningful quarter-to-quarter swings. This inherent lumpiness in robotics and simulator sales limits near-term forecasting accuracy, which investors should consider when interpreting quarterly beats or misses.

Restructuring and One-Off Costs Depress Near-Term Earnings

The consolidation of U.S. operations, including the Seattle site closure, generated about SEK 3 million of restructuring charges in Q4 and added to the cost base in 2025. Acquisition and integration-related costs totaled around SEK 23 million for the year, temporarily weighing on margins but intended to unlock longer-term efficiency gains.

Guidance and Outlook: Growth Targets Intact Despite 2026 Risk

Management reaffirmed its medium-term ambition of 10–15% annual sales growth and profitability above 15%, noting that Q4 performance was broadly aligned with these goals in both growth and margins. While the projected SEK 60–90 million 2026 license hit from Intuitive is a clear overhang, the team is banking on a broader robotics pipeline, further price increases, new product launches from the Surgical Science–IU platform and realized cost savings to sustain growth and gradually improve profitability.

Surgical Science’s earnings call painted a picture of a company executing well in its core robotics and license business, but facing real challenges on integration, FX and a key partner’s strategy shift. For investors, the appeal lies in strong cash generation, pricing power and a broadening robotics ecosystem, set against the backdrop of a sizeable 2026 revenue gap that management must now work hard to fill.